BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36307791)

  • 1. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis.
    Wang H; Xie X; Zu Q; Lu M; Chen R; Yang Z; Gao Y
    Cardiovasc Diabetol; 2022 Oct; 21(1):220. PubMed ID: 36307791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
    Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
    Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cardiovascular outcomes of biodegradable polymer drug eluting stents in patients with diabetes versus non-diabetes mellitus: a meta-analysis.
    Wang H; Zu Q; Tang H; Lu M; Chen R; Yang Z
    Cardiovasc Diabetol; 2023 Aug; 22(1):228. PubMed ID: 37644465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial.
    Koch T; Lenz T; Joner M; Xhepa E; Koppara T; Wiebe J; Coughlan JJ; Aytekin A; Ibrahim T; Kessler T; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Kufner S;
    Clin Res Cardiol; 2021 Oct; 110(10):1586-1598. PubMed ID: 34156521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
    Rozemeijer R; van Muiden IG; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Doevendans PA; Voskuil M; Stella PR
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):61-69. PubMed ID: 30604493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes after permanent polymer or polymer-free stent implantation in patients with diabetes mellitus: The ReCre8 diabetes substudy.
    van Hemert ND; Rozemeijer R; Voskuil M; Stein M; Frambach P; Rittersma SZ; Kraaijeveld AO; Leenders GEH; van der Harst P; Agostoni P; Stella PR;
    Catheter Cardiovasc Interv; 2022 Feb; 99(2):366-372. PubMed ID: 33811730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
    Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.
    Romaguera R; Gómez-Hospital JA; Gomez-Lara J; Brugaletta S; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Montanya E; Fernandez-Ortiz A; Alfonso F; Valgimigli M; Sabate M; Cequier A
    JACC Cardiovasc Interv; 2016 Jan; 9(1):42-50. PubMed ID: 26762910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials.
    Bundhun PK; Yanamala CM; Huang WQ
    BMC Cardiovasc Disord; 2017 Mar; 17(1):84. PubMed ID: 28302055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of contemporary drug-eluting stent implantation in diabetic patients: Subanalysis of a randomized controlled trial.
    van Hemert ND; Voskuil M; Rozemeijer R; Kraaijeveld AO; Rittersma SZ; Leenders GEH; Stein M; Frambach P; van der Harst P; Agostoni P; Stella PR;
    Catheter Cardiovasc Interv; 2023 Feb; 101(3):505-510. PubMed ID: 36651339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Year Clinical Outcomes After Implantation of Permanent-Polymer Versus Polymer-Free Stent: ReCre8 Landmark Analysis.
    van Hemert ND; Voskuil M; Rozemeijer R; Stein M; Frambach P; Pereira B; Rittersma SZ; Kraaijeveld AO; Leenders GEH; Timmers L; van der Harst P; Agostoni P; Stella PR;
    JACC Cardiovasc Interv; 2021 Nov; 14(22):2477-2486. PubMed ID: 34794654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes associated with Ultrathin bioresorbable polymer sirolimus eluting stents versus thin, durable polymer everolimus eluting stents following percutaneous coronary intervention in patients with type 2 diabetes mellitus: A meta-analysis of published studies.
    Deng S; Yi X; Tian Z
    Medicine (Baltimore); 2020 Dec; 99(52):e23810. PubMed ID: 33350767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
    Kufner S; Sorges J; Mehilli J; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Rheude T; Ibrahim T; Massberg S; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):784-792. PubMed ID: 27017366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
    Rozemeijer R; Benedetto D; Kraaijeveld AO; Voskuil M; Stein M; Timmers L; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
    Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):521-525. PubMed ID: 29137966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
    Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.